Dasatinib causing Intracerebral Bleeding in a Patient with Chronic Myeloid Leukaemia
Dasatinib is a potent inhibitor of BCR-ABL (break point cluster-Abelson) kinase, Src family of kinases, C-kit, and Platelet Derived Growth Factor Receptor beta (PDGFR-beta), and used in the treatment of Chronic Myeloid Leukaemia (CML), Ph-positive acute lymphoblastic leukaemia, and Acute Myeloid Leu...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2022-06-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://www.jcdr.net/articles/PDF/16434/52524_CE[Nik]_F(KR)_PF1(AG_SS)_PN(KM).pdf |
| _version_ | 1797924490465771520 |
|---|---|
| author | Santosh Govind Rathod Afaq Ahmad Khan Sajad Ahmed Geelani Reshma Roshan Javid Rasool Bhat |
| author_facet | Santosh Govind Rathod Afaq Ahmad Khan Sajad Ahmed Geelani Reshma Roshan Javid Rasool Bhat |
| author_sort | Santosh Govind Rathod |
| collection | DOAJ |
| description | Dasatinib is a potent inhibitor of BCR-ABL (break point cluster-Abelson) kinase, Src family of kinases, C-kit, and Platelet Derived Growth Factor Receptor beta (PDGFR-beta), and used in the treatment of Chronic Myeloid Leukaemia (CML), Ph-positive acute lymphoblastic leukaemia, and Acute Myeloid Leukaemia (AML). The most common side effects of dasatinib are myelosuppression, gastrointestinal disturbance, fluid retention, cutaneous eruption, and bleeding diathesis. This report is about a recently diagnosed, 45-year-old female with CML, BCR-ABL positive. After six-month therapy with imatinib, the patient developed resistance to imatinib. The treatment was changed to dasatinib 70 mg, once a day. Three months after starting the therapy, the patient showed a cytological response. While receiving dasatinib, she complained of headaches, nausea, and vomiting. Her complete blood count was within the normal limit. Coagulogram was within the normal limit. Non Contrast Computerised Tomography (NCCT) of the head showed intracerebral bleed in the right frontal area of the brain. The patient was then treated with mannitol and put on artificial ventilation. She succumbed on day fourth of the Intensive Care Unit (ICU). Dasatinib has been associated with impaired platelet aggregation, and can show fatal bleeding manifestations. |
| first_indexed | 2024-04-10T15:03:03Z |
| format | Article |
| id | doaj.art-642aca79157441e49a773483f664bb25 |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-04-10T15:03:03Z |
| publishDate | 2022-06-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-642aca79157441e49a773483f664bb252023-02-15T09:23:52ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2022-06-01166XD01XD0310.7860/JCDR/2022/52524.16434Dasatinib causing Intracerebral Bleeding in a Patient with Chronic Myeloid LeukaemiaSantosh Govind Rathod0Afaq Ahmad Khan1Sajad Ahmed Geelani2Reshma Roshan3Javid Rasool Bhat4Senior Resident, Department of Clinical Haematology, Sher-i Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.Assistant Professor, Department of Clinical Haematology, Sher-i Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.Additional Professor, Department of Clinical Haematology, Sher-i Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.Assistant Professor, Department of Clinical Haematology, Sher-i Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.Professor and Head, Department of Clinical Haematology, Sher-i Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.Dasatinib is a potent inhibitor of BCR-ABL (break point cluster-Abelson) kinase, Src family of kinases, C-kit, and Platelet Derived Growth Factor Receptor beta (PDGFR-beta), and used in the treatment of Chronic Myeloid Leukaemia (CML), Ph-positive acute lymphoblastic leukaemia, and Acute Myeloid Leukaemia (AML). The most common side effects of dasatinib are myelosuppression, gastrointestinal disturbance, fluid retention, cutaneous eruption, and bleeding diathesis. This report is about a recently diagnosed, 45-year-old female with CML, BCR-ABL positive. After six-month therapy with imatinib, the patient developed resistance to imatinib. The treatment was changed to dasatinib 70 mg, once a day. Three months after starting the therapy, the patient showed a cytological response. While receiving dasatinib, she complained of headaches, nausea, and vomiting. Her complete blood count was within the normal limit. Coagulogram was within the normal limit. Non Contrast Computerised Tomography (NCCT) of the head showed intracerebral bleed in the right frontal area of the brain. The patient was then treated with mannitol and put on artificial ventilation. She succumbed on day fourth of the Intensive Care Unit (ICU). Dasatinib has been associated with impaired platelet aggregation, and can show fatal bleeding manifestations.https://www.jcdr.net/articles/PDF/16434/52524_CE[Nik]_F(KR)_PF1(AG_SS)_PN(KM).pdffrontal brainnauseavomiting |
| spellingShingle | Santosh Govind Rathod Afaq Ahmad Khan Sajad Ahmed Geelani Reshma Roshan Javid Rasool Bhat Dasatinib causing Intracerebral Bleeding in a Patient with Chronic Myeloid Leukaemia Journal of Clinical and Diagnostic Research frontal brain nausea vomiting |
| title | Dasatinib causing Intracerebral Bleeding in a Patient with Chronic Myeloid Leukaemia |
| title_full | Dasatinib causing Intracerebral Bleeding in a Patient with Chronic Myeloid Leukaemia |
| title_fullStr | Dasatinib causing Intracerebral Bleeding in a Patient with Chronic Myeloid Leukaemia |
| title_full_unstemmed | Dasatinib causing Intracerebral Bleeding in a Patient with Chronic Myeloid Leukaemia |
| title_short | Dasatinib causing Intracerebral Bleeding in a Patient with Chronic Myeloid Leukaemia |
| title_sort | dasatinib causing intracerebral bleeding in a patient with chronic myeloid leukaemia |
| topic | frontal brain nausea vomiting |
| url | https://www.jcdr.net/articles/PDF/16434/52524_CE[Nik]_F(KR)_PF1(AG_SS)_PN(KM).pdf |
| work_keys_str_mv | AT santoshgovindrathod dasatinibcausingintracerebralbleedinginapatientwithchronicmyeloidleukaemia AT afaqahmadkhan dasatinibcausingintracerebralbleedinginapatientwithchronicmyeloidleukaemia AT sajadahmedgeelani dasatinibcausingintracerebralbleedinginapatientwithchronicmyeloidleukaemia AT reshmaroshan dasatinibcausingintracerebralbleedinginapatientwithchronicmyeloidleukaemia AT javidrasoolbhat dasatinibcausingintracerebralbleedinginapatientwithchronicmyeloidleukaemia |